The EDC is live today — see what ships now
All studies
NCT07599072From ClinicalTrials.govRecruiting

PREdiabetes GLycemic Impact and Data Evaluation

Evaluation of the Impact of Continuous Glucose Monitoring (CGM) Systems on Glycemic Control in People With Prediabetes: Postmarketing Clinical Study

  • Pre Diabetic
  • Obesity & Overweight
  • Insulin Resistance

At a glance

Phase
Phase not stated
Study type
Interventional
Sponsor
Nazarii Kobyliak
Enrolment target
80
Started
1 July 2026
Main results due
31 May 2027
Study sites
3
Registry updated
29 September 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Age of 18 years and older.
* Presence of prediabetes diagnosed according to criteria of the American Diabetes Association
* Persons who treated with diet and exercise alone or metformin on a stabilized dose for at least 3 months before the study;
* Ability to comply with protocol requirements and maintain a patient diary.
* Signed informed consent.

Exclusion Criteria:

* Presence of type 1 or type 2 diabetes;
* Decompensated liver or kidney diseases (GFR \< 45 ml/min/1. 73 m²);
* Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study;
* Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia;
* Pregnancy or lactation;
* Mental or cognitive impairments that would interfere with study participation;
* Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months;
* Recent use of any CGM within the last 12 months;
* Known allergy to sensor materials;
* Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant;
* Participation in another clinical study within the last 3 months.

What this study is about

In the sponsor’s own words, from the registry.

This prospective, randomized controlled trial evaluates whether real-time continuous glucose monitoring (CGM) improves glycemic control and lifestyle adherence in adults with prediabetes compared to conventional self-monitoring methods over a 3-month period. By analyzing metabolic markers and behavioral data, the study aims to determine the effectiveness of 24-hour monitoring as a personalized tool that increases patient adherence to lifestyle changes compared to conventional SMBG methods.

Study sites(3)

  • Bogomoletz Institute of Physiology

    Kyiv, Ukraine

    Enrolling by invitation

  • Bogomolets National Medical University

    Kyiv, Ukraine

    Recruiting

  • University Hospital of Bogomolets National Medical University

    Kyiv, Ukraine

    Recruiting

Showing 3 of 3 sites. 2 of the 3 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07599072. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me
PREdiabetes GLycemic Impact and Data Evaluation | Trialion